The Pang Lab
Dr. Pang’s research team focuses on developing Adeno-associated virus (AAV) gene therapies for the treatment of retinal diseases, especially for inherited retinal diseases. His group focuses on developing and testing these therapies in mouse models of human retinal diseases. In Dr. Pang’s lab, AAV- mediated gene therapy was used to clarify how to restore retinal function and/or how to stop retinal degeneration; whether gene therapy may prevent degeneration and/or restore full function if intervention is applied before any degeneration occurs; whether gene therapy may still be effective after significant retinal degeneration has occurred, or what kind of retinal diseases could be cured and/or what part of the degenerated retinal structure can be regenerated following gene therapy with suitable individual AAV vectors. Currently Dr. Pang’s lab is also testing novel mutant AAV vectors that can transducer cone photoreceptor following intravitreal delivery. All these are steps toward the potential application to human patients, especially those with cone/macula diseases.
Dr. Pang’s research was instrumental in the the LCA2 preclinical and clinical trials. He and his team continue to develop and test AAV vectors with the goal of future clinical trials for other retinal degenerative diseases such as achromatopsia, blue cone monochromatism (BCM), Bietti’s Crystalline Dystrophy (BCD).
For more information about Dr. Pang’s lab please contact Dr. Ji-jing Pang at email@example.com